Last reviewed · How we verify
NCT07526870: MICROTOX-PORE
Intradermal Microbotulinum Toxin for Sebum Reduction and Facial Pore Improvement
NA trial testing Botulinum Toxin Type A (Dysport®) in Facial Aging in 30 participants. Completed in 24 November 2024.
24 November 2024
Quick facts
| Lead sponsor | Instituto de Oftalmología Fundación Conde de Valenciana |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 24 July 2024 |
| Primary completion | 24 November 2024 |
| Estimated completion | 24 November 2024 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Botulinum Toxin Type A (Dysport®) — full drug profile →
Conditions studied
- Facial Aging — all drugs for Facial Aging →
- Facial Wrinkles and Rhytides Reduction — all drugs for Facial Wrinkles and Rhytides Reduction →
Sponsor
Instituto de Oftalmología Fundación Conde de Valenciana — full company profile →
Who can join
Adults 18 to 35, any sex, with Facial Aging or Facial Wrinkles and Rhytides Reduction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the efficacy and safety of microdoses of botulinum toxin type A (microtoxin) for improving periocular skin quality and reducing fine wrinkles. Botulinum toxin is commonly used in aesthetic medicine; however, its use in microdoses has been proposed to achieve more natural results with fewer adverse effects. Participants with periocular rhytids will receive intradermal injections of diluted botulinum toxin. Clinical outcomes will include improvement in skin texture, wrinkle reduction, and patient satisfaction. Safety will be assessed by monitoring adverse events. The findings of this study may help determine whether microtoxin is an effective and safe option for minimally invasive periocular rejuvenation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07526870
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Facial Aging
Currently open trials in the same condition.
- NCT07227883 — Secretome Treatment for Facial Rejuvenation · EARLY_PHASE1 · recruiting
- NCT07160777 — Performance and Safety of Semical Dermal Fillers in Facial Rejuvenation · active not recruiting
Other Instituto de Oftalmología Fundación Conde de Valenciana trials
Trials by the same sponsor.
- NCT07372014 — A Comparative Analysis of the Effectiveness of Nepafenac Combined With a Lubricant Versus a Lubricant Alone in the Treat · Phase 4 · active not recruiting
- NCT07385495 — OJO-miR: microRNA Expression in Allergic Conjunctivitis. · active not recruiting
- NCT07376148 — Fractional CO2 Laser-assisted Delivery of Hyaluronic Acid, Ascorbic Acid and Sodium DNA For Enhancing Facial Skin Qualit · Phase 4 · recruiting
- NCT07387536 — The Effectiveness of Topical Silicone Application Combined With Photoprotection in the Development of Scarring Following · Phase 4 · recruiting
- NCT07372911 — PRoTECT: Corneal Wavefront Guided PRK + Epi-off CXL vs. PTK+Epi-off CXL in Keratoconus · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07526870 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto de Oftalmología Fundación Conde de Valenciana
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07526870.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing